Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage life sciences company focused on developing central nervous system therapeutics designed to overcome the blood–brain barrier. The announcement, made on January 9, 2026, emphasizes NeOnc's differentiated platform and multiple near-term catalysts.
NeOnc's pipeline includes NEO100, a patented pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility. The company's intranasal administration strategy is designed to access the brain via olfactory and trigeminal pathways, offering a non-invasive route intended to improve adherence and enable more direct delivery. According to Stonegate, NTHI is supported by favorable tolerability with prolonged dosing and multiple near-term catalysts as the program advances toward a 2026 readout.
Key takeaways from the initiation include positive Phase 1/2a results for NEO100 announced in December, a Phase 2a top-line readout expected in mid-2026, and the anticipated closing and funding of the Quazar Investment in the near term. These milestones are expected to drive shareholder value and validate NeOnc's approach.
The full announcement, including downloadable images and bios, is available here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services.
